[ad_1]
A new study by researchers at Chongqing University of Medicine in China found that 95% of people infected with the Corunna virus developed two types of immune cells that fight the virus in 3 weeks, according to the Daily Mail.
Antibody tests are being developed in the United States and abroad to find out who already has some potential protection against HIV infection, but there are still many questions about the antibodies: if everyone is infected with it, what level of antibodies are needed to grant protection and how long does this last.
In the study, the researchers monitored the blood tests of 258 patients for signs of antibodies, and over time the researchers discovered that the body produced two types of antibodies against the infection: Immunoglobulin (LGM) and (LGG).
The first occurs early after infection, and these antibodies provide brief protection, and the researchers found that only about 40% of patients developed immunoglobulin (LGM) antibodies during the first week after infection.
But when the patients were under observation for two weeks, 95% of them had developed easily identifiable levels of antibodies (IgM).
Most important of all, immune cells make LGG antibodies, which are antibodies that take longer to develop, but are the type that can provide long-term protection.
In a confirmed study of this study, researchers in Britain collected blood samples from 69 people infected with the virus, and in 20 days, they found that all but two patients developed antibodies against the virus.
To find out the amount of protection and the period of protection these antibodies offer, Chinese researchers will need to continue their studies and perhaps expose these people to the Corona virus again, to see if these antibodies will protect them or not.
But until enough time has elapsed to complete these studies, Chinese research is an encouraging sign that the human body can learn to defend itself against the coronavirus after the first infection.
If this is the case, we can collectively develop some collective immunity that would prevent future coronavirus infection in the future from reaching epidemic levels.
